Breaking News
Sort by:
Top Post
IAVI and Moderna Launch First-in-Africa Clinical Trial of mRNA HIV Vaccine Development Program
The nonprofit scientific research organization IAVI and Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger […]
AstraZeneca Signs Licence Agreement With RQ Biotechnology for Monoclonal Antibodies Against COVID-19
AstraZeneca has entered into a licence agreement with RQ Biotechnology Ltd (RQ Bio) for a […]
RQ Bio Launches with Goal to Transform Treatment and Prevention of Viral Infectious Diseases Through Antibody Technologies
RQ Bio today emerges from stealth mode announcing its launch as a new UK-based biotechnology […]
LifeArc Co-founded Company RQ Bio Signs Licensing Agreement With AstraZeneca Worth Up to $157m Plus Royalties for Monoclonal Antibodies Against SARS-CoV-2
LifeArc today announced that RQ Biotechnology Ltd (RQ Bio), a company it co-founded, has signed […]
Roche Enters Partnership With the Global Fund to Support Low- and Middle-income Countries in Strengthening Critical Diagnostics Infrastructure
Roche (SIX: RO, ROG; OTCQX: RHHBY), through its Global Access Program, and The Global Fund […]
Janssen Discontinues Collaboration and License Agreements with Bavarian Nordic in Hepatitis B and Human Papillomavirus
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the termination of its collaboration […]
Abbott Obtains FDA Clearance for First Test that Simultaneously Detects Four Common Sexually Transmitted Infections (STIs) as Cases are on the Rise
Abbott (NYSE: ABT) announced today it has received FDA clearance for its Alinity™ m STI Assay. […]
Asceneuron Awarded Second Grant from The Michael J. Fox Foundation for Accelerated Research into Novel Parkinson's Disease Therapies
Asceneuron SA, a clinical stage company dedicated to targeting the root causes of neurodegenerative diseases, today […]
Syndrome Post-COVID: First Results of the Collaboration Between Fondamental & GeNeuro
GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune […]
Exosome-based Company Raised 5 M€ for the Development of Its New Biomedicine and Vaccines
Ciloa, a pioneer company expert in the in vivo customization of exosomes, announced today that […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more